A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

Trial Profile

A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

Planning
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Bladder cancer; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma; Seattle Genetics
  • Most Recent Events

    • 19 Jun 2017 This trial is expected to begin in the second half of 2017, according to a Seattle Genetics media release.
    • 05 Jun 2017 According to a Seattle Genetics media release,data from this trial will be used for FDA approval.
    • 05 Jun 2017 According to a Seattle Genetics media release, this trial this trial is expected to initiate in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top